1
Country: UK | Funding: $52M
Iksuda Therapeutics develops ADCs with enhanced tumor specificity. They incorporate tumor-specific, selective release and activation of payloads through mechanisms relevant to the target and tumor, thereby optimizing anticancer efficacy and improving patient safety. The company has also developed a new class of alkylating protein payloads, ProAlk. With their tailored properties to specific ADCs and broad applicability across various tumor types, Iksuda is currently developing a new ProAlk-ADC portfolio. The company's portfolio includes clinical trials against B-cell malignancies, breast cancer, gastric cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer and cervical cancer.
Iksuda Therapeutics develops ADCs with enhanced tumor specificity. They incorporate tumor-specific, selective release and activation of payloads through mechanisms relevant to the target and tumor, thereby optimizing anticancer efficacy and improving patient safety. The company has also developed a new class of alkylating protein payloads, ProAlk. With their tailored properties to specific ADCs and broad applicability across various tumor types, Iksuda is currently developing a new ProAlk-ADC portfolio. The company's portfolio includes clinical trials against B-cell malignancies, breast cancer, gastric cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer and cervical cancer.
2
Country: USA | Funding: $335.4M
Kite Pharma develops and produces immune-based cell therapies to treat cancer. Each cell therapy developed by the company is individually tailored to each patient and one-time injected. The CAR T-cell therapy manufacturing process involves collecting the patient's white blood cells, isolating and activating the T-cells, modifying the T-cells with a chimeric antigen receptor gene, culturing and expanding the T-cells and administering the modified T-cells to the same patient. Kite has a state-of-the-art manufacturing facility with full production cycle and global logistics network. The company's portfolio includes two drugs for the treatment of blood diseases, specifically diffuse large B-cell lymphoma, mantle cell lymphoma and acute lymphoblastic leukemia. The company's pipeline includes clinical trials for the treatment of lymphoma, myeloma and leukemia. Acquired by Gilead Sciences
Kite Pharma develops and produces immune-based cell therapies to treat cancer. Each cell therapy developed by the company is individually tailored to each patient and one-time injected. The CAR T-cell therapy manufacturing process involves collecting the patient's white blood cells, isolating and activating the T-cells, modifying the T-cells with a chimeric antigen receptor gene, culturing and expanding the T-cells and administering the modified T-cells to the same patient. Kite has a state-of-the-art manufacturing facility with full production cycle and global logistics network. The company's portfolio includes two drugs for the treatment of blood diseases, specifically diffuse large B-cell lymphoma, mantle cell lymphoma and acute lymphoblastic leukemia. The company's pipeline includes clinical trials for the treatment of lymphoma, myeloma and leukemia. Acquired by Gilead Sciences
3
Country: USA | Funding: $106M
Totus Medicines develops precision oral therapeutics for cancer treatment. The company uses own drug discovery platform OmniDEL, which utilizes artificial intelligence/machine learning and innovative DNA-encoded covalent library technology to search for small molecule drugs. The startup conducts ultra-high-throughput cell-based screening of these molecules using its proprietary labeling technology for cellular analysis. The company's flagship drug, TOS-358, is a precision oral drug for the treatment of cancers with PI3Kα mutations (the most frequently mutated oncogene in a wide range of cancers, for which there are currently no drugs that provide potent, specific and long-lasting inhibition without significant toxicity). TOS-358 is currently in clinical trials for the treatment of hormone receptor-positive breast, endometrial and head and neck cancers expressing PI3K-alpha mutations.
Totus Medicines develops precision oral therapeutics for cancer treatment. The company uses own drug discovery platform OmniDEL, which utilizes artificial intelligence/machine learning and innovative DNA-encoded covalent library technology to search for small molecule drugs. The startup conducts ultra-high-throughput cell-based screening of these molecules using its proprietary labeling technology for cellular analysis. The company's flagship drug, TOS-358, is a precision oral drug for the treatment of cancers with PI3Kα mutations (the most frequently mutated oncogene in a wide range of cancers, for which there are currently no drugs that provide potent, specific and long-lasting inhibition without significant toxicity). TOS-358 is currently in clinical trials for the treatment of hormone receptor-positive breast, endometrial and head and neck cancers expressing PI3K-alpha mutations.
4
Country: USA | Funding: $96M
Lantern Pharma is creating the AI platform RADR for the development of oncology drugs. It's mainly used to predict the potential response of patients to drugs. RADR uses publicly available databases, commercial clinical research and trial data, proprietary company data derived from ex vivo 3D tumor transcriptome models, genomic data and drug sensitivity data from a wide range of carefully selected sources that are constantly analyzed, tracked and updated. Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors
Lantern Pharma is creating the AI platform RADR for the development of oncology drugs. It's mainly used to predict the potential response of patients to drugs. RADR uses publicly available databases, commercial clinical research and trial data, proprietary company data derived from ex vivo 3D tumor transcriptome models, genomic data and drug sensitivity data from a wide range of carefully selected sources that are constantly analyzed, tracked and updated. Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors
5
Country: Australia | Funding: A$25M
Lumonus is a healthcare company that offers Radiation Oncology, Radiation Therapy, and Cancer treatment technology-enabled services.
Lumonus is a healthcare company that offers Radiation Oncology, Radiation Therapy, and Cancer treatment technology-enabled services.
6
Country: Denmark | Funding: $5.7B
Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.
Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.
7
Country: Germany | Funding: $2B
BioNTech is a global leader in mRNA-based immunotherapy. The company was the first to invent and commercialize a COVID-19 vaccine (in partnership with Pfizer). BioNTech is currently developing several personalized immunotherapeutic agents (vaccines) against cancer and infectious diseases, including melanoma, human papillomavirus, non-small cell lung cancer, tuberculosis and malaria. The company's flagship platform, FixVac, enables the creation of ready-to-use mRNA cancer vaccines that can be used off-shelf to a specific indication (fixed-dose vaccines). These vaccines are a fixed combination of unmutated tumor antigens encoded by mRNA, which are frequently expressed in certain types of cancer. The mRNA is delivered using a proprietary RNA-lipoplex delivery system, which is designed to enhance mRNA stability in the body and target antigen-presenting dendritic cells (DCs), the training grounds of our immune system.
BioNTech is a global leader in mRNA-based immunotherapy. The company was the first to invent and commercialize a COVID-19 vaccine (in partnership with Pfizer). BioNTech is currently developing several personalized immunotherapeutic agents (vaccines) against cancer and infectious diseases, including melanoma, human papillomavirus, non-small cell lung cancer, tuberculosis and malaria. The company's flagship platform, FixVac, enables the creation of ready-to-use mRNA cancer vaccines that can be used off-shelf to a specific indication (fixed-dose vaccines). These vaccines are a fixed combination of unmutated tumor antigens encoded by mRNA, which are frequently expressed in certain types of cancer. The mRNA is delivered using a proprietary RNA-lipoplex delivery system, which is designed to enhance mRNA stability in the body and target antigen-presenting dendritic cells (DCs), the training grounds of our immune system.
8
Country: USA | Funding: $1.9B
Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology.
Caris Life Sciences develops molecular profiling and AI-driven technologies to support precision medicine in oncology.
9
Country: USA | Funding: $1.9B
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
A simple blood test unlocks a new dimension in cancer management. Guardant360 is the only biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options.
10
Country: USA | Funding: $1.6B
IOVANCE Biotherapeutics develops personalized autologous cellular immunotherapies using tumor-infiltrating lymphocytes (TILs). A patient's natural TILs are collected and grown outside the body and then administered to the patient in a single dose. Unlike targeted cell therapies, which act on general antigen targets, IOVANCE TILs are engineered to act on specific neoantigens unique to the patient or tumor. IOVANCE's T-cell-based immunotherapy platform has potential application across multiple solid tumor types. The company has two approved drugs for the treatment of metastatic melanoma and metastatic kidney cancer. The company is also conducting clinical trials for the treatment of cervical cancer, NSCLC, endometrial cancer, and head and neck squamous cell carcinoma.
IOVANCE Biotherapeutics develops personalized autologous cellular immunotherapies using tumor-infiltrating lymphocytes (TILs). A patient's natural TILs are collected and grown outside the body and then administered to the patient in a single dose. Unlike targeted cell therapies, which act on general antigen targets, IOVANCE TILs are engineered to act on specific neoantigens unique to the patient or tumor. IOVANCE's T-cell-based immunotherapy platform has potential application across multiple solid tumor types. The company has two approved drugs for the treatment of metastatic melanoma and metastatic kidney cancer. The company is also conducting clinical trials for the treatment of cervical cancer, NSCLC, endometrial cancer, and head and neck squamous cell carcinoma.
11
Country: USA | Funding: $1.6B
Using our proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, we are discovering and developing new cellular immunotherapies for cancer. The company doesn’t intend to make its own antibodies in-house, but rather align with various companies that want to enhance their experimental antibody drugs.
Using our proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, we are discovering and developing new cellular immunotherapies for cancer. The company doesn’t intend to make its own antibodies in-house, but rather align with various companies that want to enhance their experimental antibody drugs.
12
Country: USA | Funding: $1.6B
Crinetics Pharmaceuticals explores the inner life of GPCRs to discover and develop novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers.
Crinetics Pharmaceuticals explores the inner life of GPCRs to discover and develop novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers.
13
Country: USA | Funding: $1.3B
Fate Therapeutics develops clinical drug candidates for the treatment of autoimmune diseases and cancer using its propriety iPSCs platform (induced pluripotent stem cells). These cell therapies are selectively engineered and provide novel synthetic mechanisms for regulating cellular function. The company utilizes iPSC master cell lines to generate immune system cells, including NK cells, T cells and CD34+ cells and is developing a portfolio of ready-to-use cellular immunotherapy products for the treatment of solid tumors (particularly lung, pancreatic and ovarian cancer). FT819, its first iPSC-derived CAR T-cell product candidate, demonstrates potent, dose-dependent B-cell killing comparable to that of autologous primary CAR T cells in in-vitro cytotoxicity assay using peripheral blood mononuclear cells (PBMCs) in SLE.
Fate Therapeutics develops clinical drug candidates for the treatment of autoimmune diseases and cancer using its propriety iPSCs platform (induced pluripotent stem cells). These cell therapies are selectively engineered and provide novel synthetic mechanisms for regulating cellular function. The company utilizes iPSC master cell lines to generate immune system cells, including NK cells, T cells and CD34+ cells and is developing a portfolio of ready-to-use cellular immunotherapy products for the treatment of solid tumors (particularly lung, pancreatic and ovarian cancer). FT819, its first iPSC-derived CAR T-cell product candidate, demonstrates potent, dose-dependent B-cell killing comparable to that of autologous primary CAR T cells in in-vitro cytotoxicity assay using peripheral blood mononuclear cells (PBMCs) in SLE.
14
Country: USA | Funding: $1.3B
Arcus discovers and develops innovative cancer immunotherapies based on known but under-exploited biology. Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
Arcus discovers and develops innovative cancer immunotherapies based on known but under-exploited biology. Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
15
Country: UK | Funding: $1.2B
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
16
Country: USA | Funding: $1.2B
Kura Oncology develops precision small-molecule drugs for treatment of solid tumors and blood cancers. The company discovers and tests new biomarkers of cancer signaling pathways. Kura's flagship drug, COMZIFTI, is approved for the treatment of adult patients with acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) gene mutation whose AML has relapsed or failed to improve after previous treatment and who have no other satisfactory treatment options. The company's pipeline also includes clinical trials for acute lymphoblastic leukemia, acute myeloid leukemia, advanced gastrointestinal stromal tumors, renal cell carcinoma, non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and head and neck squamous cell carcinoma.
Kura Oncology develops precision small-molecule drugs for treatment of solid tumors and blood cancers. The company discovers and tests new biomarkers of cancer signaling pathways. Kura's flagship drug, COMZIFTI, is approved for the treatment of adult patients with acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) gene mutation whose AML has relapsed or failed to improve after previous treatment and who have no other satisfactory treatment options. The company's pipeline also includes clinical trials for acute lymphoblastic leukemia, acute myeloid leukemia, advanced gastrointestinal stromal tumors, renal cell carcinoma, non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and head and neck squamous cell carcinoma.
17
Country: USA | Funding: $1.1B
Treeline Biosciences develops oral small molecules for precision treatment of cancer. It also creates protein splitters and "stickers" for situations where traditional small molecules are unlikely to be effective, focusing on pharmacology from the outset. For drug delivery, the company uses antibody-tagged conjugates (TT-ADCs), an elegant solution that avoids exposure to healthy tissues. Treeline is conducting clinical trials of two drugs for the treatment of lymphoma: TLN-121 (in-house developed), which disrupts the BCL6 protein, and TLN-254 (licensed from Hengrui Pharmaceuticals), which inhibits the EZH2 protein. The company has also begun clinical trials of a pan-KRAS inhibitor, TLN-372, for the treatment of solid tumors with certain KRAS mutations.
Treeline Biosciences develops oral small molecules for precision treatment of cancer. It also creates protein splitters and "stickers" for situations where traditional small molecules are unlikely to be effective, focusing on pharmacology from the outset. For drug delivery, the company uses antibody-tagged conjugates (TT-ADCs), an elegant solution that avoids exposure to healthy tissues. Treeline is conducting clinical trials of two drugs for the treatment of lymphoma: TLN-121 (in-house developed), which disrupts the BCL6 protein, and TLN-254 (licensed from Hengrui Pharmaceuticals), which inhibits the EZH2 protein. The company has also begun clinical trials of a pan-KRAS inhibitor, TLN-372, for the treatment of solid tumors with certain KRAS mutations.
18
Country: UK | Funding: $1.1B
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
19
Country: UK | Funding: $1.1B
Autolus uses advanced CAR-T cell therapy to treat hematological malignancies and solid tumors. While CAR T-cell therapy has revolutionized cancer treatment, it can also cause significant immunotoxicity. Autolus has developed a novel CAR-construct with rapid binding kinetics that is similar to natural T cells and provides improved tolerability in patients with certain types of leukemia. Furthermore, Autolus addresses the issue of immunotoxicity through a personalized dosing approach. The company is also seeking to adopt CAR-T therapy to patients with acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, T-cell lymphoma and solid tumors. It is supporting several ongoing CAR-T clinical trials that are opening up new treatment options and offering new hope for these patients.
Autolus uses advanced CAR-T cell therapy to treat hematological malignancies and solid tumors. While CAR T-cell therapy has revolutionized cancer treatment, it can also cause significant immunotoxicity. Autolus has developed a novel CAR-construct with rapid binding kinetics that is similar to natural T cells and provides improved tolerability in patients with certain types of leukemia. Furthermore, Autolus addresses the issue of immunotoxicity through a personalized dosing approach. The company is also seeking to adopt CAR-T therapy to patients with acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, T-cell lymphoma and solid tumors. It is supporting several ongoing CAR-T clinical trials that are opening up new treatment options and offering new hope for these patients.
20
Country: Switzerland | Funding: $1B
ADC Therapeutics is focused on the creation of proprietary Antibody Drug Conjugates (ADCs) for the therapy of both solid and hematological cancers. It uses monoclonal antibodies specific to specific tumor antigens conjugated to a innovative class of highly potent pyrrolobenzodiazepine (PBD)-based warheads to specifically kill cancer cells. The company is expanding ZYNLONTA into earlier stages of DLBCL and indolent lymphomas. In addition, IND-enabling efforts are in progress for the Company’s exatecan-based, prostate-specific membrane antigen.
ADC Therapeutics is focused on the creation of proprietary Antibody Drug Conjugates (ADCs) for the therapy of both solid and hematological cancers. It uses monoclonal antibodies specific to specific tumor antigens conjugated to a innovative class of highly potent pyrrolobenzodiazepine (PBD)-based warheads to specifically kill cancer cells. The company is expanding ZYNLONTA into earlier stages of DLBCL and indolent lymphomas. In addition, IND-enabling efforts are in progress for the Company’s exatecan-based, prostate-specific membrane antigen.
21
Country: USA | Funding: $1B
Allogene Therapeutics is working to overcome the limitations of autologous CAR T therapy by creating allogeneic CAR T cell (AlloCAR T) products that utilize T cells from healthy donors. These cells are isolated in a manufacturing facility, engineered to express CAR T cells (that recognize and destroy disease) and genetically modified to limit the autoimmune response when administered to a patient. These cells are then stored for use as needed. The company estimates that a single production cycle is sufficient to treat over 100 patients, significantly reducing the cost of therapy. The company's pipeline includes candidates for large B-cell lymphoma and renal cell carcinoma (ALLO-316 is the first and only allogeneic CAR T cell therapy to show promising results in the treatment of solid tumors). The company operates its own manufacturing complex for clinical and commercial production, analytical testing and distribution of cell products.
Allogene Therapeutics is working to overcome the limitations of autologous CAR T therapy by creating allogeneic CAR T cell (AlloCAR T) products that utilize T cells from healthy donors. These cells are isolated in a manufacturing facility, engineered to express CAR T cells (that recognize and destroy disease) and genetically modified to limit the autoimmune response when administered to a patient. These cells are then stored for use as needed. The company estimates that a single production cycle is sufficient to treat over 100 patients, significantly reducing the cost of therapy. The company's pipeline includes candidates for large B-cell lymphoma and renal cell carcinoma (ALLO-316 is the first and only allogeneic CAR T cell therapy to show promising results in the treatment of solid tumors). The company operates its own manufacturing complex for clinical and commercial production, analytical testing and distribution of cell products.
22
Country: Israel | Funding: $1B
Novocure is developing a new treatment for solid tumors known as tumor polytherapy (TTFields). TTFields are low-intensity alternating electric fields, particularly at intermediate frequencies that disrupt cancer cell division through physical interaction with key molecules during mitosis. TTFields do significantly affect healthy cells, as they have different properties (including division rate, morphology and electrical properties) compared to cancer cells. The company's TTFields pipeline includes therapies against glioblastoma, metastatic non-small cell lung cancer and pancreatic cancer. The company also produces FDA-approved portable devices for the treatment of GB and mNSCLC. These devices also work via creating electric fields that can slow or stop cancer cell division.
Novocure is developing a new treatment for solid tumors known as tumor polytherapy (TTFields). TTFields are low-intensity alternating electric fields, particularly at intermediate frequencies that disrupt cancer cell division through physical interaction with key molecules during mitosis. TTFields do significantly affect healthy cells, as they have different properties (including division rate, morphology and electrical properties) compared to cancer cells. The company's TTFields pipeline includes therapies against glioblastoma, metastatic non-small cell lung cancer and pancreatic cancer. The company also produces FDA-approved portable devices for the treatment of GB and mNSCLC. These devices also work via creating electric fields that can slow or stop cancer cell division.
23
Country: USA | Funding: $896.6M
Zentalis is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics.
Zentalis is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics.
24
Country: Japan | Funding: $737.6M
Rakuten Medical is a privately funded clinical-stage biotechnology company. The Company develops medicines for the treatment of cancer based on photoimmunotherapy platform.
Rakuten Medical is a privately funded clinical-stage biotechnology company. The Company develops medicines for the treatment of cancer based on photoimmunotherapy platform.
25
Country: China | Funding: $737.6M
Rakuten Aspyrian is developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy.
Rakuten Aspyrian is developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy.
26
Country: USA | Funding: $694.1M
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity.
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity.
27
Country: USA | Funding: $630.8M
ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop in immune cell therapies.
ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop in immune cell therapies.
28
Country: USA | Funding: $620M
Century Therapeutics is harnessing the power of adult stem cells to develop curative therapies for cancer. It develops iPSC-derived, allogeneic immune cell therapy products for cancer
Century Therapeutics is harnessing the power of adult stem cells to develop curative therapies for cancer. It develops iPSC-derived, allogeneic immune cell therapy products for cancer
29
Country: USA | Funding: $566.8M
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, multiple sclerosis (MS).
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, multiple sclerosis (MS).
30
Country: USA | Funding: $545.9M
Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.
Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.
31
Country: China | Funding: $504.7M
Ascentage Pharma is a China-based, global-oriented company focused on the discovery and development of targeted small molecule anti-cancer therapies. The company leverages own breakthrough chemistry to synthesize inhibitors that target proteins (Bcl-2, Bcl-2/Bcl-xL, IAP, and MDM2) and signaling pathways that define key cancer hallmarks (e.g., BCR-ABL1, ALK, and FAK inhibitors). It also develops therapies such as PROTACs (Protein Acid Carcinogenesis Acids) that target traditionally untreatable proteins involved in oncogenesis. The company is conducting clinical trials of drugs against chronic lymphocytic leukemia, acute myeloid leukemia, small lymphocytic lymphoma, adrenocortical carcinoma, malignant peripheral nerve sheath tumor, and non-small cell lung cancer.
Ascentage Pharma is a China-based, global-oriented company focused on the discovery and development of targeted small molecule anti-cancer therapies. The company leverages own breakthrough chemistry to synthesize inhibitors that target proteins (Bcl-2, Bcl-2/Bcl-xL, IAP, and MDM2) and signaling pathways that define key cancer hallmarks (e.g., BCR-ABL1, ALK, and FAK inhibitors). It also develops therapies such as PROTACs (Protein Acid Carcinogenesis Acids) that target traditionally untreatable proteins involved in oncogenesis. The company is conducting clinical trials of drugs against chronic lymphocytic leukemia, acute myeloid leukemia, small lymphocytic lymphoma, adrenocortical carcinoma, malignant peripheral nerve sheath tumor, and non-small cell lung cancer.
32
Country: USA | Funding: $445M
Rubius is developing a new class of drugs, Red-Cell Therapeutics. Rubius is using advanced cellular therapies that harness the unique, inherent properties of red cells and marry them to the creative power of genetic engineering.
Rubius is developing a new class of drugs, Red-Cell Therapeutics. Rubius is using advanced cellular therapies that harness the unique, inherent properties of red cells and marry them to the creative power of genetic engineering.
33
Country: USA | Funding: $445.4M
CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics.
CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics.
34
Country: USA | Funding: $418M
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes.
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes.
35
Country: USA | Funding: $400M
Celgene spinout that aims is to develop cells from placentas against blood cancers and is founded on the use of stem cells from placentas. The goal is to create therapies across autoimmune and degenerative disease, immuno-oncology, and functional regeneration.
Celgene spinout that aims is to develop cells from placentas against blood cancers and is founded on the use of stem cells from placentas. The goal is to create therapies across autoimmune and degenerative disease, immuno-oncology, and functional regeneration.
36
Country: France | Funding: $393.5M
Cellectis has developed genome editing technology TALEN, which enables it to create more affordable, ready-to-use allogeneic CAR T-cell therapies. Its technology offers protection against graft-versus-host disease, reduces the risk of rejection and improves safety by integrating a self-destruct mechanism. Using this technology, the company is developing a pipeline of several candidates against non-Hodgkin's lymphoma, large B-cell lymphoma, renal cell carcinoma and melanoma. Cellectis is also advancing PulseAgile technology, which uses electroporation (controlled electric fields) to deliver messenger RNA molecules into cells. It utilizes a unique electric field waveform, which, combined with a proprietary buffer solution, allows molecules such as nucleases to effectively penetrate cells while maintaining high cell viability.
Cellectis has developed genome editing technology TALEN, which enables it to create more affordable, ready-to-use allogeneic CAR T-cell therapies. Its technology offers protection against graft-versus-host disease, reduces the risk of rejection and improves safety by integrating a self-destruct mechanism. Using this technology, the company is developing a pipeline of several candidates against non-Hodgkin's lymphoma, large B-cell lymphoma, renal cell carcinoma and melanoma. Cellectis is also advancing PulseAgile technology, which uses electroporation (controlled electric fields) to deliver messenger RNA molecules into cells. It utilizes a unique electric field waveform, which, combined with a proprietary buffer solution, allows molecules such as nucleases to effectively penetrate cells while maintaining high cell viability.
37
Country: Belgium | Funding: $369.7M
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
38
Country: USA | Funding: $356M
Be Biopharma engineers B-cell therapies. The applications of B cells include everything from autoimmune diseases to cancer and monogenic disorders, which are caused by variation in a single gene.
Be Biopharma engineers B-cell therapies. The applications of B cells include everything from autoimmune diseases to cancer and monogenic disorders, which are caused by variation in a single gene.
39
Country: USA | Funding: $355.2M
PathAI's goal is to improve cancer diagnosis using artificial intelligence. PathAI’s services solve the most challenging pathology problems faced by the research and pharmaceutical industry.
PathAI's goal is to improve cancer diagnosis using artificial intelligence. PathAI’s services solve the most challenging pathology problems faced by the research and pharmaceutical industry.
40
Country: USA | Funding: $347.9M
Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.
Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.
41
Country: USA | Funding: $329.2M
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
42
Country: USA | Funding: $328M
Shattuck develops cancer immunotherapy, with immune checkpoint blockade, has provided profound benefit for patients with late-stage cancers.
Shattuck develops cancer immunotherapy, with immune checkpoint blockade, has provided profound benefit for patients with late-stage cancers.
43
Country: USA | Funding: $325M
Obsidian Therapeutics develops precision cell and gene therapies to expand the capabilities of adoptive cancer immunotherapy. The company has developed the cytoDRiVE platform, which leverages drug-responsive domains (DRDs) to control protein function using an FDA-approved small molecule, and is continually expands its library of identified DRDs of varying sizes and purposes. The company's lead drug, OBX-115, is an experimental therapy using tumor-infiltrating lymphocytes genetically modified to produce a membrane-bound (non-secreted) cytokine (IL15). Obsidian is conducting a multicenter clinical trial for the treatment of advanced melanoma and non-small cell lung cancer.
Obsidian Therapeutics develops precision cell and gene therapies to expand the capabilities of adoptive cancer immunotherapy. The company has developed the cytoDRiVE platform, which leverages drug-responsive domains (DRDs) to control protein function using an FDA-approved small molecule, and is continually expands its library of identified DRDs of varying sizes and purposes. The company's lead drug, OBX-115, is an experimental therapy using tumor-infiltrating lymphocytes genetically modified to produce a membrane-bound (non-secreted) cytokine (IL15). Obsidian is conducting a multicenter clinical trial for the treatment of advanced melanoma and non-small cell lung cancer.
44
Country: USA | Funding: $324.9M
Accelerating the fight against cancer requires the entire industry to work together. Our products connect community oncologists, academics, hospitals, life science researchers and regulators on a shared technology platform. Flatiron Health gathers and analyzes data on cancer treatments and sells software based on those insights
Accelerating the fight against cancer requires the entire industry to work together. Our products connect community oncologists, academics, hospitals, life science researchers and regulators on a shared technology platform. Flatiron Health gathers and analyzes data on cancer treatments and sells software based on those insights
45
Country: USA | Funding: $324M
Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.
Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.
46
Country: Czech Republic | Funding: $316.9M
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit.
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit.
47
Country: USA | Funding: $313M
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
48
Country: China | Funding: $312.8M
Harbour BioMed is a global biopharmaceutical company developing innovative therapeutics in the field of immuno-oncology and inflammatory diseases.
Harbour BioMed is a global biopharmaceutical company developing innovative therapeutics in the field of immuno-oncology and inflammatory diseases.
49
Country: USA | Funding: $311.2M
Personalis provides researchers and clinicians accurate DNA sequencing and interpretation of human exomes and genomes. We support researchers engaging in case-control, family-based, or proband-only genomic studies of disease, pharmacogenomics, and cancer. Our ACE (Accuracy and Content Enhanced) Technology supplements a standard exome or genome, substantially increasing its medically-relevant coverage and accuracy.
Personalis provides researchers and clinicians accurate DNA sequencing and interpretation of human exomes and genomes. We support researchers engaging in case-control, family-based, or proband-only genomic studies of disease, pharmacogenomics, and cancer. Our ACE (Accuracy and Content Enhanced) Technology supplements a standard exome or genome, substantially increasing its medically-relevant coverage and accuracy.
50
Country: USA | Funding: $310M
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.
